Skip to main content

Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 21, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, Feb. 21, 2025 -- For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for moderate or severe COPD exacerbations compared with dipeptidyl peptidase 4 inhibitors (DPP-4is), according to a study published online Feb. 10 in JAMA Internal Medicine.

Avik Ray, M.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues conducted a comparative effectiveness study to assess the risk for moderate or severe COPD exacerbations among patients aged 40 years or older with T2D and active COPD who initiated treatment with SGLT-2is versus DPP-4is; GLP-1 RAs versus DPP-4is; and SGLT-2is versus GLP-1 RAs (27,991; 32,107; and 36,218 pairs, respectively).

The researchers found that the risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is versus DPP-4is and among those treated with GLP-1 RAs versus DPP-4is (9.26 versus 11.4 per 100 person-years [hazard ratio, 0.81] and 9.89 versus 11.49 per 100 person-years [hazard ratio, 0.86], respectively), with minimal differences observed among those treated with SGLT-2is versus GLP-1 RAs. Across sensitivity and subgroup analyses, the results were consistent.

"These findings suggest that SGLT-2is and GLP-1 RAs may be preferable to DPP4is when deciding among glucose-lowering medications for patients with T2D and active COPD," the authors write. "However, given the observational nature of the study, there is potential for residual or unmeasured confounding, and findings from similar clinical studies and clinical trials will help corroborate these results."

Several authors disclosed ties to the pharmaceutical industry; one author disclosed being an expert witness in litigation against inhaler manufacturers.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists

WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...

Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes

WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...

GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM

THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.